Skip to Main Content

Paper Details

Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Cancer Res
60
2019
-PD-1 Ab, AXL, CD8+, CD8+ T cells, IFN, LCK, M1-polarized intratumoral macrophages, MER, RTK, RXDX, RXDX-106, TAM, TAM RTK, TAM RTKs, TYRO3, cancer, cancer cells, cancers, dendritic cells, immune and tumor cells, immune cells, intratumoral macrophages, mice, multiple, natural killer cells, pan, receptor tyrosine kinases, syngeneic tumor models, tumor, tumor-infiltrating leukocytes, tyrosine

Datasets

Release 1.2